{"query":"*[content.slug.current == \"minimal-residual-disease\"] {\n ...,\n content {\n ...,\n 'platforms': platforms[]-\u003e\n }\n }","result":[{"_updatedAt":"2021-07-20T18:55:38Z","content":{"_type":"object","description":"We are leaders in the field
when it comes to monitoring measurable/minimal residual disease (MRD), which can be a deciding factor in a patient's treatment regimen.\n","text":[{"_type":"block","style":"normal","_key":"3db7e66f8ce8","markDefs":[],"children":[{"_type":"span","marks":[],"text":"Multiple
studies have demonstrated that patients with no MRD detected have better overall survival (OS) and progression-free survival (PFS) rates, when compared to patients with detected MRD. MRD detection requires highly sensitive methods to assess these hidden
cells. Hematogenix has validated multiple and complementary MRD assays by NGS and Flow Cytometry for AML and B-cell malignancies (e.g., CLL, MM, and others). ","_key":"8b134012192b"}]}],"seo":{"description":"We are leaders in the field when it comes to
monitoring measurable/minimal residual disease (MRD), which can be a deciding factor in a patient's treatment regimen.","title":"Measurable/Minimal Residual Disease (MRD)"},"title":"Minimal Residual Disease (MRD)","slug":{"_type":"slug","current":"minimal-residual-disease"}},"_createdAt":"2021-03-12T10:16:16Z","_rev":"xJLmvHmMyKEcO9uAV1WAz8","_type":"minimalResidualDisease","_id":"minimalResidualDisease"}],"ms":4}